iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) is running for the top in the market this morning, and for good reason. The company announced that IBM Watson Health has selected it to receive free use of the IBM Clinical Development solution. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Heads Up On IBM Clinical Development Solution

In the press release, iBio said that IBM Watson Health will be providing the company with the IBM Clinical Development solution free of charge for a period of 18 months.

In the release, the company said that IBM Watson Health began offering its ICD solution to eligible trial sponsor organizations in an attempt to assist the medical community in developing options for COVID-19 vaccines and treatments. The company has received interest in its offering from hospitals, sponsors, contract research organizations and acedemic institutions.

As part of the program, the IBM Clinical Development solution is now being used as part of 15 COVID-19 disease clinical trials.

As far as IBIO goes, we’re not far off from data in their fight against COVID-19. In fact, the company is working on the development of two vaccines, including IBIO-200 and IBIO-201. In fact, it is expected that data from preclinical immunization studies of these vaccine candidates will be available in the third quarter of this year.

In a statement, Tom Isett, Co-Chairman and CEO at IBIO, had the following to offer:

We are deeply appreciative of IBM’s vote-of-confidence, which recognizes the potential of iBio’s COVID-19 vaccine development efforts from among the hundreds of organizations that applied for access to IBM’s ICD solution. This technology helps to support the rapid and efficient undertaking of clinical trials of iBio’s COVID-19 vaccine candidates. It also complements our FastPharming System’s core speed, quality and scale-up advantages in the development of vaccines and therapeutics. Through strategic collaborations like this one, we believe iBio is now poised with the tools, technology and capital necessary to compete in the fight against COVID-19.

The above statement was followed up by Mary Varghese Presti, Vice President of Life Sciences at IBM Watson Health. Here’s what she had to say:

The COVID-19 pandemic is an unprecedented global public health crisis and there is an increasing sense of urgency to develop safe and effective treatments as infection rates continue to escalate at an alarming rate. We are committed to leveraging our ICD solution to help accelerate the timelines for COVID-19 clinical trials and are enabling access to the platform, free of charge, for relevant trial sponsors. We are inspired by iBio’s commitment, as well as all of the other leaders in the life sciences community, as they apply their expertise and ingenuity to help millions of patients worldwide. IBM is proud to play a meaningful role in this ambitious effort.

What We’ll Be Watching For Ahead

Moving forward, we’ll be keeping a close eye on iBio. In particular, we’re looking forward to the company’s continued work to bring a vaccine for COVID-19 to market. As the United States continues to work to reopen restaurants, retail stores, and more, the virus continues to spread.

Many argue that the only way to stop the virus from spreading is through the use of a vaccine. So, vaccine development is very important these days. When it comes to IBIO, the company has the potential to produce one of the leading vaccines that eventually hit the market.

First and foremost, we’ve talked about the company’s FastPharming Facility. The facility was commissioned specifically to fight pandemic outbreaks and gives the company in house manufacturing at speeds unmatched by competitors. Now, the company has the IBM Clinical Development platform on its side, which is likely to further speed up the time to potential approval.

All in all, if you watching the COVID-19 vaccine race, IBIO stock should definitely be on your watchlist.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.